Literature DB >> 27258812

Assessment of CTLA-4 Deficiency-Related Autoimmune Choroidopathy Response to Abatacept.

Carol L Shields1, Emil A T Say1, Arman Mashayekhi1, Sunir J Garg2, James P Dunn2, Jerry A Shields1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27258812     DOI： 10.1001/jamaophthalmol.2016.1013

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  8 in total

1.  Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient.

Authors:  Ester M van Leeuwen; Eloy Cuadrado; Anke M Gerrits; Esther Witteveen; Godelieve J de Bree
Journal:  J Clin Immunol       Date:  2018-05-23       Impact factor: 8.317

Review 2.  Inflammatory Manifestations of Systemic Diseases in the Central Nervous System.

Authors:  David A Lapides; Mark M McDonald
Journal:  Curr Treat Options Neurol       Date:  2020-07-29       Impact factor: 3.598

3.  Submacular choroiditis in common variable immunodeficiency associated with a pathogenic mutation in the tumor necrosis factor gene.

Authors:  Michelle Y Peng; Judy J Chen; Aisha Ahmed; Emmett T Cunningham
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-06

Review 4.  Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.

Authors:  N Verma; S O Burns; L S K Walker; D M Sansom
Journal:  Clin Exp Immunol       Date:  2017-07-21       Impact factor: 4.330

Review 5.  Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.

Authors:  M Jamee; S Hosseinzadeh; N Sharifinejad; M Zaki-Dizaji; M Matloubi; M Hasani; S Baris; M Alsabbagh; B Lo; G Azizi
Journal:  Clin Exp Immunol       Date:  2021-05-03       Impact factor: 5.732

Review 6.  Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.

Authors:  Cristiane de Jesus Nunes-Santos; Sergio D Rosenzweig
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 7.  New pharmacotherapy options for noninfectious posterior uveitis.

Authors:  Uwe Pleyer; Piergiorgio Neri; Christoph Deuter
Journal:  Int Ophthalmol       Date:  2021-02-25       Impact factor: 2.031

8.  Myeleterosis in an ALPS5 patient with primary immune dysregulation syndrome.

Authors:  Hongyu Long; Zhao Chen; Bo Xiao; Beisha Tang; Hong Jiang
Journal:  CNS Neurosci Ther       Date:  2020-03-17       Impact factor: 5.243
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.